Curriculum Delivery: Develop and deliver engaging, effective, and well-structured lesson plans that cater to the diverse learning needs and academic levels of students in secondary, junior college, and IB settings.
We are looking for one motivated PhD student to join our research team at the UKM Medical Molecular Biology Institute (UMBI), Universiti Kebangsaan Malaysia (UKM).
Job Summary: The Researcher I (Biology) role reports to the Head of Biological Research and involves supporting and conducting biological research projects, including invitro studies and human clinical trial-related activities, with a focus on oleochemicals, phytonutrients, and bioactive ingredients derived from palm oil. Candidates should possess a Bachelor's or Master's degree in Biology, Biomedical Science, Biotechnology, Molecular Biology, Cell Biology, Biochemistry, Pharmacology, Nutritional Science, or a related life sciences field, with a PhD considered an advantage, particularly for Researcher II applicants. Researcher I requires 2–3 years of relevant experience in biological, biomedical, nutritional, cosmetic, pharmaceutical, or life sciences research, while Researcher II requires 3–5 years of experience, preferably including leadership of experimental workstreams, project coordination, or support for clinical studies.
Teach weekly Upper Secondary (Pure and Combined Science Biology) and/or JC (H1/H2 Biology) classes, in person and online, in line with the latest SEAB syllabuses
Working closely with a variety of students based across the world - including the US, Asia, Australia, and Europe (within a time zone appropriate for you)
Design, plan and conduct in vitro biological studies to evaluate the efficacy, mechanism of action and biological activity of active ingredients and formulations.
Chugai Pharmabody Research Pte. Ltd. (“CPR”) was established in Singapore as a wholly-owned subsidiary of Chugai Pharmaceutical Co., Ltd (Chugai), a member of Roche group, in January 2012 and started operations on July 2, 2012. Located at Biopolis, (Geneo from September 2026) in Singapore, it aims to generate new antibody drugs based on Chugai’s proprietary antibody engineering technologies, such as recycling antibody, sweeping antibody, bispecific antibody, various Fc engineered antibodies, and other new antibody engineering technologies that are underdevelopment.